Background {#Sec1}
==========

Lines of evidence indicate that maternal nutrition during pregnancy and lactation is closely related to the adequate development of offspring \[[@CR1]\]. The offspring's metabolism is dependent on substrates from maternal nutrients, and one of the most important nutritional substances is fatty acid (FA) \[[@CR2]\]. FAs are responsible for the growth of cell membranes, as well as for maintaining their appropriate fluidity and permeability, \[[@CR3]\] and they are involved in energetic and metabolic processes \[[@CR4]\]. The maternal FA level is positively related to the offspring's fat percentage, and transporting FAs from mother to offspring is positively correlated with offspring development, particularly during the late gestation period, when deposition of fat in the fetus increases sharply \[[@CR5]\]. It has been shown that maternal triglycerides (TG) and free fatty acid levels have a close relationship with both weight and fat mass of infants \[[@CR3]\]. FA deficiency and disruption in the maternal-placental offspring metabolism lead to malnutrition of the fetus, and metabolic diseases may appear in the later life of the offspring \[[@CR6], [@CR7]\].

Short chain fatty acids (SCFA) can be found in foods and are the main products of the intestinal fermentation of soluble fiber, which contains abundant quantities of acetate, propionate and butyrate \[[@CR8], [@CR9]\]. Butyrate acts as the major intestinal fuel, supplying 60--70 % of the energy needs of the colonocytes \[[@CR10], [@CR11]\]. Increasing evidence have shown that butyrate affects body lipid metabolism \[[@CR12]--[@CR14]\]. Several studies have discussed the treatment of butyrate reduced intracellular lipolytic activity or enhanced adipogenesis \[[@CR11], [@CR15]\]. Other reports have suggested that incubation of 3 T3-L1 adipocytes with high concentrations of butyrate resulted in an increased lipolytic response \[[@CR16]\]. In a high-fat animal model, treatment with sodium butyrate (SB) can lead to loss of body weight or reverse gains in body weight and adiposity \[[@CR17], [@CR18]\].

Regarding supplemental SB in the maternal diet, lines of evidence have indicated that SB can promote the growth performance of weaning pigs \[[@CR19]--[@CR21]\]. However, the effect of a maternal SB supplement on the maternal lipid metabolism is unknown. Furthermore, if SB influences the mother's lipid metabolism, it remains largely unclear whether this effect will exert its action on offspring lipid accumulation.

The liver performs a key role in lipid metabolism, importing free fatty acids, manufacturing and exporting lipids to provide energy, and storing excess lipids, thus making the liver responsible for lipid homeostasis \[[@CR22]\]. It has been shown that maternal pre-pregnancy body weight is associated with offspring hepatic fat storage \[[@CR23]\]. Maternal obesity may result in offspring overgrowth and increased lipid deposition in fetuses \[[@CR24]\]; moreover, an excess of lipid deposition can lead to postnatal hepatic dysfunction and even non-alcoholic steatohepatitis \[[@CR25]\]. The influence of maternal SB on offspring hepatic lipid metabolism needs to be investigated.

We conducted this study to determine the effects of maternal butyrate supplementation on the potential relationship between maternal lipid metabolism in white adipose tissue and offspring hepatic lipid accumulation during pregnancy and the lactation period. This is the first study to examine whether a relationship exists between maternal serum NEFA and offspring hepatic lipid accumulation. Overall, our results will provide scientific research to help protect offspring liver from damage.

Methods {#Sec2}
=======

Animals and treatments {#Sec3}
----------------------

Twenty-four ten week old female virgin SD rats were purchased from the experimental animal center of Jiangsu University. All rats were housed in pairs at 20--24 °C and 40--60 % humidity on a 12 h light--dark cycle with adlibitum access to food and water.

After one week of acclimatization, the rats were randomly divided into a 1:2 ratio. All rats received a normal chow diet (20 % protein) until pregnancy was confirmed through the presence of a post-copulatory plug and vaginal smear the next morning. All of the males were removed after the females became pregnant. The pregnant rats were fed either a normal diet or a 1 % sodium butyrate diet until the end of the lactation period. The above foods were all customized from the Jiangsu Xie Tong Company. SB was blended into the normal diet as it was formed, and the food was stored at 4 °C after it was pelleted.

The slaughter and sampling procedures complied with the "Guidelines on Ethical Treatment of Experimental Animals" (2006) No.398 set by the Ministry of Science and Technology, China.

Blood and tissue sample collection {#Sec4}
----------------------------------

At 21 days of age, the weaning rats and mothers were weighed and anesthetized with an intraperitoneal injection of Nembutal, and then they were euthanized. Blood was drawn from the abdominal aorta and centrifuged at 3000 rpm for 10 min at 4 °C for serum collection. Serums were stored at −20 °C until they were analyzed. The fresh livers from the weaning rats and the subcutaneous adipose tissue derived from the mothers were immediately removed and weighed after laparotomy. The samples were snap-frozen in liquid nitrogen and stored at −80 °C.

Assay of serum concentration of cholesterol and hepatic contents of cholesterol and fatty acids {#Sec5}
-----------------------------------------------------------------------------------------------

Serum concentration of total cholesterol (Tch) was measured with a biochemical automatic analyzer (Hitachi 7020; HITACHI) using a commercial cholesterol assay kit (E1015; Applygen Technologies, Inc.). Serum concentrations of LDL-cholesterol (LDL-C) and HDL-cholesterol were measured with a biochemical automatic analyzer (Hitachi 7020; HITACHI) using a commercial cholesterol assay kit (KP712, KF253 Wako Pure Chemical Industries, Ltd. Wako), respectively. Serum concentration of TG was measured with a biochemical automatic analyzer (Hitachi 7020; HITACHI) using a commercial TG assay kit (E1013; Applygen Technologies, Inc.). Serum non-esterified fatty acid (NEFA) concentrations were determined using the Wako NEFA Cacyllcoenzyme A synthetase acyl-coenzyme A oxidase assay method. Hepatic total cholesterol concentration was measured using a tissue total cholesterol assay kit (E1015; Applygen Technologies, Inc.) following the manufacturer's instructions. Hepatic concentration of total triglyceride was quantified with a biochemical automatic analyzer (Hitachi 7020; HITACHI) using a commercial TG assay kit (E1013; Applygen Technologies, Inc.).

Assay of maternal serum concentration of fatty acid composition {#Sec6}
---------------------------------------------------------------

Serum fatty acids (FAs) composition was analyzed according to the method of Hossain Z \[[@CR26]\]. Briefly, total lipids from the serum were extracted with chloroform-methanol (2:1, vol:vol) containing 0.01 % butylated hydroxytoluene (Sigma-Aldrich) by using heptadecanoic acid as an internal standard (Sigma-Aldrich). The fatty acid extracts were methylated with methanolic hydrochloric acid. The fatty acid methyl esters were analyzed by an Agilent 6890 N gas chromatograph with a flame ionization detector (Agilent Technologies) as mentioned. Serum FAs are shown as percentage (%, wt/wt) composition. The gas chromatograph was equipped with a split/split less injector, and the column was a fused silica DB-225MS capillary column (30 m × 0.25 mm thickness; Supelco). The gas chromatograph oven was programmed as follows: 70 °C for 2 min, increase 25 °C/min, 190 °C for 3 min, increase 2 °C /min, 220 °C for 15 min, increase 45 °C, and finally 250 °C for 10 min. Samples were run with a 5:1 split ratio, and helium was used as the carrier gas with a column flow rate of 0.8 ml/min. Temperature for the injector was operated at 280 °C. Temperature for the combustion reactor was set at 960 °C. The fatty acids were determined by comparing the peak retention times with standards (Sigma, St Louis, MO).

Protein extraction and Western blot analysis {#Sec7}
--------------------------------------------

Total proteins were extracted from 60 mg of frozen liver samples as described previously. Protein concentrations were determined using a Pierce BCA Protein Assay kit (Pierce, Rockford, IL, USA). 48 μg of liver protein was then loaded onto 10 % or 15 % SDS-PAGE gel. Western blot analysis of target proteins was carried out according to the protocols provided by the manufacturer. The primary antibodies used in the Western blot analysis are listed in Table [1](#Tab1){ref-type="table"}. GAPDH or β-actin was used as the loading control in the Western blot analysis.Table 1Antibodies used in our experimentAntibody descriptionCompanyItem No.Dilution ratioACSL1santa cruzsc-490081:200ACSS1santa cruzsc-3738471:200SCD1santa cruzsc-147201:200PPARγbioworldBS-15871:500SREBP1santa cruzsc-3661:200HSLbioworldBS27421:500P-HSLsanta cruzsc-1396561:500ATGLbioworldBS67571:500CPT1αabcamab838631:500UCP3bioworldBS67571:500GPR43santa cruzsc-329061:200PKAbioworldBS26481:500SREBP2santa cruzsc-130681:200HMGCRbioworldBS66251:500CYP27A1bioworldbs21921:200LXRsanta cruzsc-130681:200LDLRproteintech10785-1-AP1:1000C/EBPβsanta cruzsc-150×1:200FABP1bioworldBS75331:500CD36bioworldBS78611:500GAPDHbioworldMB001H1:10000β-actinbioworldAP00601:10000

Statistical analyses {#Sec8}
--------------------

The results from the experiment were analyzed using the statistics software SPSS for Windows version 20.0. Independent-samples *T*-Test was used to analyze all data. The results were presented as the mean ± standard error (SE). Differences were considered statistically significant when the p value was less than 0.05. Numbers of replicates used in the experiment were noted in the tables and figures.

Results {#Sec9}
=======

Body weight, liver weight and litter size {#Sec10}
-----------------------------------------

The mother's body weight showed no significant changes between the Control (Con) group (315.16 ± 9.67) and the SB group (376.56 ± 9.18). The litter weight in the Con group (102.00 ± 2.92) was not significant compared to the SB group (107.03 ± 3.20). The litter size in the Con (*n* = 6) was (13.85 ± 0.34) compared to the SB group (16.00 ± 0.53). The offspring weight and liver weight in the Con group in the weaning rats were comparable to the SB group (*P* \< 0.05), as is shown in Table [4](#Tab4){ref-type="table"}.

Maternal serum NEFA, triglyceride, lipoprotein lipase and cholesterol concentration {#Sec11}
-----------------------------------------------------------------------------------

As is shown in Table [2](#Tab2){ref-type="table"}, serum content of NEFA was significantly increased (*P* \< 0.05) in the sodium butyrate--supplemented rats compared with the Con group, though the maternal serum Tch, TG, LDLC and HDLC showed no obvious changes. The serum concentrations of LPL in the mothers also demonstrated no difference.Table 2Serum concentration of total cholesterol, triglyceride and non-esterified fatty acid in maternal rats (*n* = 6)VariablesConSB*P*-valueTch (mmol/L)1.84 ± 0.181.60 ± 0.100.77TG (mmol/L)0.48 ± 0.070.52 ± 0.060.68HDL-C (mmol/L)1.06 ± 0.080.95 ± 0.080.50LDL-C (mmol/L)0.19 ± 0.020.15 ± 0.010.92LPL (g/L)12.00 ± 0.8710.71 ± 1.130.59NEFA (mmol/L)0.68 ± 0.050.86 ± 0.050.03Tch, total cholesterol; LDL-C, LDL-cholesterol; HDL-C, HDL-cholesterol; LPL, lipoprotein lipase, NEFA, non-esterified fatty acids

The fatty acid composition of the maternal serum {#Sec12}
------------------------------------------------

The fatty acid composition of the maternal serum is shown in Table [3](#Tab3){ref-type="table"}. The other fatty acid components tested did not change significantly, except the Cis-9-Oleic Methyl ester (c18:1n9c), which increased significantly compared to the Con group.Table 3The non-esterified fatty acid composition in maternal serum (in % of total fatty acids)VariablesConSB*P*-valuec6:040.7 ± 3.630.9 ± 6.60.20c14:112.0 ± 0.714.7 ± 2.10.21C18:09.6 ± 2.011.0 ± 2.50.69c18:1n9c14.3 ± 2.222.9 ± 3.10.05c18:2n6c11.6 ± 0.210.1 ± 1.30.31c20:4n65.8 ± 1.23.1 ± 0.80.10c6:0, caproic acid; c14:1, myristoleic acid; C18:0, stearic acid; c18:1n9, oleic acid;c18:2n6c, linoleic acid; c20:4n6, arachidontic acid

The concentration of Tch and TG in offspring liver and serum {#Sec13}
------------------------------------------------------------

As is shown in Table [4](#Tab4){ref-type="table"}, the serum content of NEFA was significantly increased (*P* \< 0.05) in the sodium butyrate-supplemented rats. No significant changes in concentrations of TG were observed in the offspring serum. However, the offspring serum content of total cholesterol, LDL-C and HDL-C were significantly increased (*P* \< 0.01) compared to the Con group. Moreover, the hepatic concentration of TG and Tch in offspring born to the sodium butyrate supplemented group increased significantly (*P* \< 0.05).Table 4Serum concentration of fatty acids, total cholesterol, triglyceride and hepatic content of total cholesterol, triglyceride in weaning rats, body weight and liver weightVariablesConSB*P*-valueBody weight (g)68.51 ± 1.6467.67 ± 3.060.81Liver weight (g)3.20 ± 0.133.18 ± 0.180.80HepaticTch (mmol/L)4.39 ± 0.075.42 ± 0.300.00HepaticTG (mmol/L)15.83 ± 1.1722.72 ± 2.570.04Serum Tch (mmol/L)2.88 ± 0.093.43 ± 0.140.00Serum TG (mmol/L)0.76 ± 0.140.76 ± 0.201.00Serum HDL-C (mmol/L)1.20 ± 0.031.50 ± 0.070.00Serum LDL-C (mmol/L)0.99 ± 0.061.25 ± 0.070.01Serum NEFA (mmol/L)0.51 ± 0.050.65 ± 0.040.05Tch, total cholesterol; LDL-C, LDL-cholesterol; HDL-C, HDL-cholesterol; NEFA, non-esterified fatty acid(Mean values with their standard errors, *n* = 6)

Expression of proteins related to lipid metabolism in the maternal subcutaneous adipose tissue {#Sec14}
----------------------------------------------------------------------------------------------

As is shown in Fig. [1](#Fig1){ref-type="fig"}, the proteins involved in lipolysis, including ATGL, HSL and P-HSL were significantly higher in the SB group (*P* \< 0.05) (Fig. [1b](#Fig1){ref-type="fig"}). Yet, no significant changes were detected for the content of proteins long-chain acyl-CoA synthetase-1 (ACSL1), Acyl-CoA Synthetase-1 (ACSS1), stearyl coenzyme A dehydrogenase (SCD) (Fig. [1a](#Fig1){ref-type="fig"}), or in the content of SREBP1c and PPARγ in the subcutaneous adipose tissue (Fig. [1a](#Fig1){ref-type="fig"}). Moreover, the protein content of carnitine palmitoyltransferase (CPTI-α) 1A and UCP3uncoupling protein 3 involved in energy metabolism did not change in the SB group compared with the Con group (Fig. [1b](#Fig1){ref-type="fig"}). In addition, the content of proteins GPR43 and PKA were significantly higher in the SB group (*P* \< 0.05) (Fig. [2](#Fig2){ref-type="fig"}).Fig. 1Effect of maternal sodium butyrate on lipid metabolism in maternal adipose tissue. **a** The expression of proteins related to lipogenesis. **b** The expression of proteins involved in lipolysis. Values are mean ± SEM, \**P* \< 0.05, compared with control (*n* = 6)Fig. 2The GPR43 (**a**) and PKA (**b**) protein content in maternal adipose tissue. Values are mean ± SEM, \**P* \< 0.05, compared with control (*n* = 6)

Expression of proteins related to lipid metabolism in the offspring liver {#Sec15}
-------------------------------------------------------------------------

The results showed that the LDLR protein active in cholesterol uptake increased significantly in the SB group compared with the Con group (Fig. [3c](#Fig3){ref-type="fig"}). While, the proteins expression involved in cholesterol synthesis, including 3-hydroxy-methyl-glutaryl-CoA reductase (HMGCR) and Sterol Regulatory Element Binding Protein2 (SREBP2) showed no significant changes (Fig. [3a](#Fig3){ref-type="fig"}). Additionally, the proteins related to cholesterol degradation, such as sterol 27-hydroxylase (CYP27A1), liver X-activated receptor (LXR) (Fig. [3b](#Fig3){ref-type="fig"}) remained unchanged compared to the Con group.Fig. 3Effect of maternal sodium butyrate on hepatic expression of cholesterol metabolic proteins in weaning rats. **a** Protein expression of SREBP2 and HMGCR; **b** Protein expression of CYP27A1 and LXR; **c** Protein expression of LDLR. Values are mean ± SEM, \**P* \< 0.05, compared with control (*n* = 6)

The protein content of FABP1 and CD36 related to fatty acid transport in the offspring liver increased significantly (Fig. [4c](#Fig4){ref-type="fig"}), though proteins related to TG synthesis such as ACSS1, ACSL1, FAS (Fig. [4a](#Fig4){ref-type="fig"}), sterol regulatory element binding protein 1 (SREBP1) and CCAAT-enhancer binding proteins (CEBPβ) (Fig. [4b](#Fig4){ref-type="fig"}) were the same in both groups. Meanwhile, no alterations were detected in the content of P-HSL protein levels in two groups (Fig. [4c](#Fig4){ref-type="fig"}).Fig. 4Effect of maternal sodium butyrate on hepatic expression of lipid metabolic proteins in weaning rats. **a** Proteins involved in lipogenesis; **b** Protein expression of SREBP1 and CEBP-b. **c** Protein expression of P-HSL,FABP1 and CD36. Values are mean ± SEM, \**P* \< 0.05, compared with control (*n* = 6)

Discussion {#Sec16}
==========

It is well established that resistant starch and dietary fibers can produce SCFA, which can raise intestinal and circulating SCFA, including butyrate acid. Besides acting as an important energy source of the colonocytes, butyrate is of special interest for its countless positive effects on the gut and other tissues \[[@CR27]\]. In a rodent obesity model, both supplementation with butyrate and oral administration of acetate have been demonstrated to suppress weight gain \[[@CR12]\]. In a maternal diet, supplementing with butyrate has been shown to increase reproductive performance and enhanced anti-oxidant capacity \[[@CR28]\]. In the present study, we demonstrated for the first time (as far as we know) the influence of a butyrate supplement on maternal and offspring lipid metabolism.

The present study demonstrated that the increasing concentration of serum NEFA in maternal serum was consistent with the increasing lipolysis in the adipose tissue. The higher protein expressions of ATGL, HSL and P-HSL were observed in maternal adipose tissue from the SB group. ATGL could stimulate lipid mobilization when it was localized at the lipid droplet surface, and it could catalyze the original step in TG hydrolysis \[[@CR29], [@CR30]\]. HSL was thought to be the rate-limiting enzyme of the first lipolytic step \[[@CR30], [@CR31]\]. Moreover, previous studies have shown that oleic acid has a potentially protective effect on cancers and cell growth \[[@CR32]\]. Similarly, an increased composition of oleic acid was found in our present study. Meanwhile, we investigated the protein levels involved in lipogenesis, including ACSL1, ACSS1, SCD and the key nuclear transcription factors containing PPARγ and SREBP1; none of these showed obvious changes.

GPR43 is one of the FA receptors and is present in many different kinds of tissues, including adipose tissue. In order to understand the relationship between sodium butyrate and maternal lipolysis, we determined the GPR43 protein expression in the maternal adipose tissue. Notably, the GPR43 protein level was elevated in the present study. It has been shown that butyrate can activate PKA through cAMP after binding the receptor \[[@CR33]\], and other research has demonstrated that PKA can activate and phosphorylate the downstream molecules of HSL \[[@CR33]--[@CR35]\]. In the present study, the results showed that the PKA protein level increased significantly in the SB group. All of our results taken together showed that sodium butyrate increased the protein expression of GPR43, which elevated the P-HSL through the higher PKA protein level.

To further clarify the effect of a maternal sodium butyrate supplement on offspring lipid metabolism, we measured the serum lipid indexes in the offspring. Our results found that the concentration of serum NEFA in the SB group is significantly higher than in the Con group. When this result is considered in association with the increased maternal serum NEFA, it may be inferred that the enhanced maternal serum NEFA may have increased the transport capacity in the placenta and resulted in the increased serum NEFA in the offspring. Also, there is a report exhibiting that a maternal SB supplement can increase the fatty acid transport in the placenta \[[@CR36]\]. However, we supplemented the SB during gestation and the lactation period; therefore, it is also possible that the maternal NEFA was transported through the milk \[[@CR37]\]. Further study is needed to clarify this issue.

The liver is a main actor in the process of fatty acid metabolism, and the present results showed a higher hepatic content of TG and Tch after maternal butyrate treatment. We further investigated the expression of lipid metabolism related proteins in the offspring liver. Previous studies have suggested that the fatty acid-binding protein known as FABP1 is present at high levels in murine liver \[[@CR38]\], and it is a key regulator of hepatic lipid metabolism and acts as an intracellular acceptor of fatty acids following their cellular uptake and trafficking \[[@CR39]\]. The increased FABP1 protein expression in the offspring liver in the present study indicates a higher uptake of free fatty acids, and these findings are consistent with the higher concentration of NEFA in the offspring serum. The main membrane proteins associated with FABPs are the fatty acid transfer proteins (FAT/CD36 and FATP) \[[@CR40]\]. We thus found a significant up-regulation of CD36 protein levels in the offspring liver of the maternal sodium butyrate group. Another important finding of the present study is the higher LDLR protein levels in the offspring liver of those exposed to the maternal sodium butyrate supplement. LDL particles are the main carrier of cholesterol to peripheral tissues in mammals, and the hepatic LDLR is important for maintaining cholesterol homeostasis \[[@CR41]\]. These results are in agreement with the elevated Tch in the offspring liver treated with maternal sodium butyrate. However, the other proteins related to lipogenesis and lipolysis detected in the present study showed no obvious changes compared with the control group. It is possible that the increased offspring hepatic lipid deposition in the maternal SB group resulted mainly from the increased hepatic lipid uptake from the circulating serum.

Conclusion {#Sec17}
==========

In summary, SD rats treated with maternal sodium butyrate throughout gestation and lactation showed increased lipolysis in the maternal adipose tissue and in lipid accumulation in the offspring liver. Follow-up studies are needed to identify the possible pathway of fatty acid transport between mother and offspring after the maternal sodium butyrate supplement was administered.

Abbreviations {#Sec18}
=============

ACSL1, long-chain acyl-CoA synthetase-1; ACSS1, Acyl-CoA Synthetase-1; ATGL, adipose triglyceride lipase; CD36, fatty acid transfer proteins; CEBPβ, CCAAT-enhancer binding proteins; CON, control; CPT-1A, Carnitine palmitoyltransferase 1A; CYP27A1, sterol 27-hydroxylase; FABP1, fatty acid binding proteins; FAS, fatty acid synthetase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GPR43, G-coupled protein receptor 43; HSL, hormone sensitive lipase; LDL-R, Low-density lipoprotein receptor; LXR, liver X-activated receptor; NEFA, non esterified fatty acid; p-HSL, phosphorylated-hormone sensitive lipase; PKA, proteinkinase A; PPARγ, peroxisome proliferative activated receptor γ; SB, sodium butyrate; SCD, Stearoyl-CoA desaturase; SREBP1, sterol regulatory element binding protein 1; Tch, total cholesterol; TG, triglyceride; UCP3, Uncoupling protein 3

We thank Jun Guo and Yanping Huang for their technical support on data collection.

Funding {#FPar1}
=======

This study was supported by the National Natural Science Foundation of China (31572482), and the National Basic Science Research Program (973 program) of China (2015CB150300).

Availability of data and materials {#FPar2}
==================================

The dataset supporting the conclusions of this article is included within the article.

Authors' contributions {#FPar3}
======================

JBZ performed the research, researched data, drafted the manuscript. SXG determined the serum fatty acids levels. JLC contributed to discussion part and reviewed the manuscript. XJY and RQZ provided experimental concepts and design, offered scientific direction, and reviewed the manuscript. All authors read and approved the final manuscript.

Consent for publication {#FPar4}
=======================

Written informed consent was obtained from the participants for the publication of this report.

Competing interest {#FPar5}
==================

The authors declare that they have no competing interests.

Ethics approval and consent to participate {#FPar6}
==========================================

The study protocol complied with the "Guidelines on Ethical Treatment of Experimental Animals" (2006) No. 398 set by the Ministry of Science and Technology, China, which is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC).
